Made available in DSpace on 2015-03-26T13:47:27Z (GMT). No. of bitstreams: 1 texto completo.pdf: 923002 bytes, checksum: d038ed7630080e45d27557c298896b35 (MD5) Previous issue date: 2006-12-15 / Fundação de Amparo a Pesquisa do Estado de Minas Gerais / Sixteen bovines belonged to Bos taurus taurus species, serumly and parasitically negatives to hemoparasites, were divided in four groups of inoculation: Control groups, Saponine group, Treatment group I and Treatment group II. The following study had the objective to evaluate and measure the cellular immune response and the protection given to bovines, through simultaneous vaccination of synthetics immunogenics SBbo 23290 in opposite sides (Treatment I) and through vaccination of the same immunogenics SBm 7462 + SB 23290 in the same dose (Treatment II). All animals were inoculated three times, through subcutaneous, with intermissions of thirty days. The challenges were done thirty and thirty-four days after third inoculation, placing 2000 grubs of Ripicephalus Boophilus miroplus, out of hemoparasites, and lately inoculating the strain of Babesia bovis UFV1 ninth passing, in the concentration of 1 x 106 Babesias/ml, respectively. The results show that, along the study, animals vaccinated in two forms related obtained an alteration of the sub population of lymphocytes present in the peripheral blood. Among the population of lymphocytes studied, a bigger increase for the sub population of cells B CD21+ was seen. Through the study of kinetic production of interleukin 4, was valued the activation of blood peripheral mononuclear cells (PBMC) cultivated after vaccination of animals and beforehand stimulated together with synthetic peptides SBbo 23290 e SBm 7462. The quantification of IL-4 production showed low levels for Treatment group I, Treatment group II and Saponine group. / Dezesseis bovinos pertencentes a espécie Bos taurus taurus, negativos sorologicamente e parasitologicamente à hemoparasitas foram divididos em quatro grupos de inoculação: grupo Controle, grupo adjuvante Saponina, grupo Tratamento I e grupo com Tratamento II. O presente estudo teve como objetivo avaliar a resposta imune celular e a proteção conferida aos bovinos, pela vacinação simultânea com os imunógenos sintéticos SBm 7462 e SBbo 23290 em lados opostos (Tratamento I) e pela vacinação dos mesmos imunógenos SBm 7462 + SBbo 23290 na mesma dose (Tratamento II). Todos os animais foram inoculados três vezes, via subcutânea, com intervalos de trinta dias. O desafio foi feito 30 e 34 dias após a terceira inoculação, colocando-se 2000 larvas de Ripicephalus Boophilus microplus, livres de hemoparasitas, e posteriormente inoculando a cepa de Babesia bovis UFV1 - 9ª passagem, na concentração de 1x 106 Babesias/mL, respectivamente. Os resultados demonstraram que, ao longo do estudo, os animais vacinados das duas formas desenvolveram uma modificação das sub-populações de linfócitos presentes no sangue periférico. Dentre as populações de linfócitos estudadas houve um maior aumento para as sub-populações de células B CD21+. Por meio de um estudo da cinética de produção de Interleucina-4 avaliou-se a ativação de células sanguíneas mononucleares periféricas (PBMC) cultivadas após a vacinação dos animais e previamente estimuladas juntamente com os peptídeos sintéticos SBbo 23290 e SBm 7462 .Os resultados da produção de IL-4 apresentaram baixos níveis para os grupos Tratamento I, Tramento II e Saponina.

This study compared the immunogenicity of inactivated SARS-CoV-2 vaccines between people living with HIV (PLWH) and HIV-negative individuals. We recruited 120 PLWH and 53 HIV-negative individuals aged 18-59 years who had received an inactivated SARS-CoV-2 vaccine in two Chinese cities between April and June 2021. Blood samples were tested for immunogenicity of the inactivated SARS-CoV-2 vaccines. The prevalence and severity of adverse events associated with SARS-CoV-2 vaccines were similar between PLWH and HIV-negative individuals. The seropositivity of neutralizing activity against authentic SARS-CoV-2, of the total amount of antibody (total antibody) and of S-IgG were 71.3%, 81.9%, and 92.6%, respectively, among fully vaccinated PLWH. Among all participants, PLWH had lower neutralizing activity, total antibody, S-IgG, and T-cell-specific immune response levels, compared to HIV-negative individuals, after controlling for types of vaccine, time interval between first and second dose, time after receiving the second dose, and sociodemographic factors. PLWH with a longer interval since HIV diagnosis, who received their second dose 15-28 days prior to study commencement, and who had an interval of ≥21 days between first and second dose had higher neutralizing activity levels. The immunogenicity of the inactivated SARS-CoV-2 vaccines was lower among PLWH as compared to HIV-negative individuals. Vaccination guideline specific for PLWH should be developed.